JP2011526294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526294A5 JP2011526294A5 JP2011516646A JP2011516646A JP2011526294A5 JP 2011526294 A5 JP2011526294 A5 JP 2011526294A5 JP 2011516646 A JP2011516646 A JP 2011516646A JP 2011516646 A JP2011516646 A JP 2011516646A JP 2011526294 A5 JP2011526294 A5 JP 2011526294A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- group
- alkoxy
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 101
- -1 heterocycloalkyloxy Chemical group 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 20
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 125000006413 ring segment Chemical group 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004001 thioalkyl group Chemical group 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 230000000698 schizophrenic effect Effects 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims 5
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 5
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 0 **c(cc1)ccc1-c1c(*)cccc1 Chemical compound **c(cc1)ccc1-c1c(*)cccc1 0.000 description 23
- 125000005605 benzo group Chemical group 0.000 description 9
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- IWSMBQGLMBANFK-UHFFFAOYSA-N CC(C)(C)N(C(CC1)C2)C1CC2=O Chemical compound CC(C)(C)N(C(CC1)C2)C1CC2=O IWSMBQGLMBANFK-UHFFFAOYSA-N 0.000 description 1
- HWTOGAWRASXJNF-UHFFFAOYSA-N CC(C)N(CC1)CC1=O Chemical compound CC(C)N(CC1)CC1=O HWTOGAWRASXJNF-UHFFFAOYSA-N 0.000 description 1
- HCTBGWWIFCBFGV-UHFFFAOYSA-N CC(C)N(CC1C2)C2CC1=O Chemical compound CC(C)N(CC1C2)C2CC1=O HCTBGWWIFCBFGV-UHFFFAOYSA-N 0.000 description 1
- SIKTVUHUQZNEPY-UHFFFAOYSA-N CN(CCC1)CC1=O Chemical compound CN(CCC1)CC1=O SIKTVUHUQZNEPY-UHFFFAOYSA-N 0.000 description 1
- YTZQMCKKXWLCFC-UHFFFAOYSA-N CN1C2COCC1C2 Chemical compound CN1C2COCC1C2 YTZQMCKKXWLCFC-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7559908P | 2008-06-25 | 2008-06-25 | |
| US61/075,599 | 2008-06-25 | ||
| US13885608P | 2008-12-18 | 2008-12-18 | |
| US61/138,856 | 2008-12-18 | ||
| PCT/US2009/048608 WO2009158467A2 (en) | 2008-06-25 | 2009-06-25 | Di-substituted phenyl compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526294A JP2011526294A (ja) | 2011-10-06 |
| JP2011526294A5 true JP2011526294A5 (enExample) | 2012-08-09 |
Family
ID=41137470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516646A Pending JP2011526294A (ja) | 2008-06-25 | 2009-06-25 | ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110224204A1 (enExample) |
| EP (1) | EP2297131A2 (enExample) |
| JP (1) | JP2011526294A (enExample) |
| KR (1) | KR20110025984A (enExample) |
| CN (1) | CN102131798A (enExample) |
| AU (1) | AU2009262150A1 (enExample) |
| BR (1) | BRPI0914775A2 (enExample) |
| CA (1) | CA2729220A1 (enExample) |
| MX (1) | MX2011000177A (enExample) |
| RU (1) | RU2011102587A (enExample) |
| WO (1) | WO2009158467A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2516867T3 (es) * | 2009-10-30 | 2014-10-31 | Janssen Pharmaceutica Nv | Ligandos de PDE10 radiomarcados |
| EP2423181A1 (en) | 2010-07-28 | 2012-02-29 | Prous Institute For Biomedical Research S.A. | Multitarget substituted biphenyl diol derivatives |
| WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| KR20140009372A (ko) | 2011-02-18 | 2014-01-22 | 알러간, 인코포레이티드 | 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체 |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| WO2014009305A1 (en) * | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| EP2860177A3 (en) * | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| SG11201908512YA (en) | 2017-03-16 | 2019-10-30 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| TWI903299B (zh) | 2018-03-08 | 2025-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| FI3853218T3 (fi) | 2018-09-18 | 2025-04-15 | Crinetics Pharmaceuticals Inc | Somatostatiinin modulaattoreita ja niiden käyttöjä |
| TWI841768B (zh) * | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| KR102811543B1 (ko) | 2019-10-16 | 2025-05-23 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
| US20230357159A1 (en) * | 2020-08-04 | 2023-11-09 | Precision Bio-Therapeutics S.R.L. | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors |
| JP2024506715A (ja) | 2021-02-17 | 2024-02-14 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| KR20250117433A (ko) | 2022-12-13 | 2025-08-04 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 아형-2 수용체(sst2r) 표적 치료제 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0453210A3 (en) * | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
| CN1034934C (zh) * | 1990-06-19 | 1997-05-21 | 明治制果株式会社 | 血管紧张素ii拮抗性吡啶衍生物的制备方法 |
| GB2264710A (en) * | 1992-03-04 | 1993-09-08 | Merck & Co Inc | Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element |
| JPWO2004002484A1 (ja) * | 2002-06-26 | 2005-10-27 | 協和醗酵工業株式会社 | ホスホジエステラーゼ阻害剤 |
| US7524870B2 (en) * | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| CA2650976A1 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| WO2008033455A2 (en) * | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
-
2009
- 2009-06-25 CA CA2729220A patent/CA2729220A1/en not_active Abandoned
- 2009-06-25 US US13/001,361 patent/US20110224204A1/en not_active Abandoned
- 2009-06-25 AU AU2009262150A patent/AU2009262150A1/en not_active Abandoned
- 2009-06-25 WO PCT/US2009/048608 patent/WO2009158467A2/en not_active Ceased
- 2009-06-25 RU RU2011102587/04A patent/RU2011102587A/ru not_active Application Discontinuation
- 2009-06-25 CN CN2009801332872A patent/CN102131798A/zh active Pending
- 2009-06-25 MX MX2011000177A patent/MX2011000177A/es not_active Application Discontinuation
- 2009-06-25 BR BRPI0914775A patent/BRPI0914775A2/pt not_active IP Right Cessation
- 2009-06-25 EP EP09770999A patent/EP2297131A2/en not_active Withdrawn
- 2009-06-25 JP JP2011516646A patent/JP2011526294A/ja active Pending
- 2009-06-25 KR KR1020117001927A patent/KR20110025984A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526294A5 (enExample) | ||
| JP2011526295A5 (enExample) | ||
| JP2011526282A5 (enExample) | ||
| CN114127053B (zh) | 一种取代吡嗪化合物、其制备方法和用途 | |
| AU2022260495A1 (en) | Parp1 inhibitors and uses thereof | |
| ES2870203T3 (es) | Compuesto derivado tricíclico, método para prepararlo y composición farmacéutica que comprende el mismo | |
| JP6511430B2 (ja) | がんの治療のための化合物および組成物 | |
| US9617257B2 (en) | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | |
| JP2013544261A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2012526107A5 (enExample) | ||
| CA2785923A1 (en) | Therapeutic compounds and related methods of use | |
| CN102131800A (zh) | 5元和6元杂环化合物 | |
| CA2840627A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| JP2012506381A5 (enExample) | ||
| CA2602348A1 (en) | Cyclopentapyridine and tetrahydroquinoline derivatives | |
| JP2025518592A (ja) | 二環式誘導体ｐａｒｐ阻害剤及びその用途 | |
| CN105722840A (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| JP2008511574A5 (enExample) | ||
| TW202426426A (zh) | 雜環化合物 | |
| JP2003513066A5 (enExample) | ||
| CN110128425B (zh) | 作为pi3k/mtor抑制剂的芳环或杂环取代的稠合喹啉化合物 | |
| CN119451964A (zh) | Fgfr2和fgfr3抑制剂及其用途 | |
| JP2012528185A5 (enExample) | ||
| JP2021187859A (ja) | 複素環化合物の医薬用途 |